ClinicalTrials.gg
CompletedNCT04178967ADvocate2Updated May 24, 2023Results posted

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis

A Phase 3 interventional study of Lebrikizumab and Placebo in Atopic Dermatitis, sponsored by Eli Lilly and Company. Completed at 89 sites in 8 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-05-24.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
445
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing lebrikizumab in Dermatitis, Atopic — 4 open to participants now, 7 under way, 4 of them phase 3. lebrikizumab · Dermatitis, Atopic.

Enrollment
3rd of 24
445 · median 252
Started
2019
with 1 other
Phase 3
17 of 24
2 open now
Registered
5th of 24
by date
Lead sponsor
14 of 24
Eli Lilly and Company

Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, this one is the 3rd largest by enrollment, is one of 2 that started in 2019, is one of 17 in phase 3, and was the 5th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 24 studies testing lebrikizumab in Dermatitis, Atopic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About lebrikizumab

lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing lebrikizumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of moderate-to-severe atopic dermatitis utilizing a 16-week induction treatment period and a 36-week long-term maintenance treatment period.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • Eczema
  • Dermatitis
  • Dermatitis, Atopic
  • Skin Diseases
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adults and adolescents (≥12 years and ≥40 kg)
  • Chronic atopic dermatitis (according to American Academy of Dermatology Consensus Criteria) that has been present for ≥1 year before the screening visit
  • Eczema Area and Severity Index (EASI) score ≥16 at the baseline visit
  • Investigator Global Assessment (IGA) score ≥3 (scale of 0 to 4) at the baseline visit
  • ≥10% body surface area (BSA) of atopic dermatitis involvement at the baseline visit
  • History of inadequate response to treatment with topical medications; or determination that topical treatments are otherwise medically inadvisable

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with dupilumab or tralokinumab
  • Treatment with topical , calcineurin inhibitors or phosphodiesterase-4 inhibitors such as crisaborole within 1 week prior to the baseline visit
  • Treatment with any of the following agents within 4 weeks prior to the baseline visit:

    • /immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase inhibitors, azathioprine, methotrexate, etc.)
    • Phototherapy and photochemotherapy (PUVA) for AD
  • Treatment with the following prior to the baseline visit:

    • An drug within 8 weeks or within 5 half-lives (if known) of baseline, whichever is longer
    • Cell-depleting biologics, including to rituximab, within 6 months of baseline
    • Other biologics within 5 half-lives (if known) or 16 weeks of baseline, whichever is longer
  • Treatment with a live (attenuated) vaccine within 12 weeks of the baseline visit or planned during the study
  • Uncontrolled chronic disease that might require bursts of oral corticosteroids, e.g., co-morbid severe uncontrolled asthma
  • Evidence of active acute or chronic hepatitis
  • History of (HIV) infection or positive HIV serology
  • History of , including mycosis fungoides, within 5 years before the screening visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved non- squamous or basal cell carcinoma of the skin
  • Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
445 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Induction Period (Baseline-Week 16): Two subcutaneous (SC) injections of Placebo as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14. Maintenance Period (Week 16-Week 52): Two placebo SC injections as loading dose on Week 16 and Week 18. One placebo SC injection Q2W until Week 50.

    Other: Placebo

  • Experimental
    Lebrikizumab Q2W

    Induction Period (Baseline-Week 16): 500 milligram (mg) Lebrikizumab (2 x 250 mg) SC injections as a loading dose at Baseline and Week 2 visits followed by a single 250 mg Lebrikizumab injection Q2W from Week 4 until Week 14. Maintenance Period (Week 16-Week 52): One 250 mg Lebrikizumab SC injection and one placebo SC injection as maintenance loading dose on Week 16 and Week 18. One 250 mg Lebrikizumab SC injection Q2W until Week 50.

    Biological: Lebrikizumab

  • Experimental
    Lebrikizumab Q4W

    Maintenance Period (Week 16-Week 52): One 250 mg Lebrikizumab SC injection and one placebo SC injection as maintenance loading dose on Week 16 and two placebo SC injections on Week 18. One 250 mg Lebrikizumab SC injection Every 4 weeks (Q4W) on Weeks 20, 24, 28, 32, 36, 40, 44, and 48. One placebo SC injection Q4W on Weeks 22, 26, 30, 34, 38, 42, 46, and 50.

    Biological: Lebrikizumab · Other: Placebo

  • Experimental
    Escape Arm (Lebrikizumab Q2W)

    Maintenance Period (Week 16-Week 52): Participants who require topical or systemic rescue treatment for atopic dermatitis during the Induction Period, or are non-responders at Week 16, will be eligible for treatment in an Escape Arm where participants will receive open-label lebrikizumab Q2W from Week 16 through Week 52. In addition, participants who do not maintain an acceptable response during the Maintenance Period (have an EASI score \<50% of baseline), will be eligible for the Escape Arm.

    Biological: Lebrikizumab

Interventions

  • BiologicalLebrikizumab

    Subcutaneous injection

    Also known as: LY3650150, DRM06

  • OtherPlacebo

    Subcutaneous Injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16

    The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

    Time frame: Baseline to Week 16

  2. Percentage of Participants Achieving Eczema Area And Severity Index (EASI-75) (≥75% Reduction in EASI Score) From Baseline to Week 16

    The EASI assesses objective physician estimates of 2 dimensions of AD - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI-75 responder is defined as a participant who achieves a ≥ 75% reduction from baseline in the EASI score.

    Time frame: Baseline to Week 16

Secondary outcomes

  1. Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 2

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

    Time frame: Baseline to Week 2

  2. Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 4

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

    Time frame: Baseline to Week 4

  3. Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

    Time frame: Baseline to Week 16

  4. Percentage of Participants Achieving EASI-90 (≥90% Reduction in EASI Score) From Baseline to Week 16

    The EASI assesses objective physician estimates of 2 dimensions of AD - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI-90 responder is defined as a participant who achieves a ≥ 90% reduction from baseline in the EASI score.

    Time frame: Baseline to Week 16

  5. Percentage Change in Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16

    Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable." Least Squares (LS) Mean was calculated using analysis of covariance (ANCOVA) model with treatment and randomization strata (region, disease severity, age) as fixed factors and baseline value as covariate.

    Time frame: Baseline, Week 16

  6. Percentage of Participants With a Pruritus NRS Score of ≥4-points at Baseline Who Achieve a ≥4-point Reduction in Pruritus NRS Score From Baseline to Week 16

    Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

    Time frame: Baseline to Week 16

  7. Percentage of Participants With a Pruritus NRS Score of ≥5-points at Baseline Who Achieve a ≥4-point Reduction in Pruritus NRS Score From Baseline to Week 16

    Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

    Time frame: Baseline to Week 16

  8. Percentage Change in EASI Score From Baseline to Week 16

    The EASI assesses objective physician estimates of 2 dimensions of AD - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). LS Mean was calculated using ANCOVA model with treatment, stratification factors of geographic region, age group, baseline IGA score (IGA 3 versus 4) as fixed factors baseline value as covariate.

    Time frame: Baseline, Week 16

  9. Change From Baseline in Percent Body Surface Area (BSA) at Week 16

    The BSA affected by AD will be assessed for 4 separate body regions: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region will be assessed for disease extent ranging from 0% to 100% involvement. BSA was calculated using the participant's palm using the 1% rule, 1 palm was equivalent to 1% with estimates of the number of palms it takes to cover the affected AD area. Maximum number of palms were 10 palms for head and neck (10%), 20 palms for upper extremities (20%), 30 palms for trunk, including axilla and groin (30%), 40 palms for lower extremities, including buttocks (40%). Percent of BSA for a body region was calculated as = total number of palms in a body region \* % surface area equivalent to 1 palm. Overall percent BSA of all 4 body regions ranges from 0% to 100 % with higher values representing greater severity of AD.

    Time frame: Baseline, Week 16

  10. Percentage of Participants Achieving EASI-90 From Baseline to Week 4

    The EASI assesses objective physician estimates of 2 dimensions of AD - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI-90 responder is defined as a participant who achieves a ≥ 90% reduction from baseline in the EASI score.

    Time frame: Baseline to Week 4

  11. Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16

    The DLQI is a 10-item, validated questionnaire used to assess the impact of skin disease on the quality of life of an affected person. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment, over the previous week. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". Questions are scored from 0 to 3, giving a possible total score range from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life). A high score is indicative of a poor quality of life. LS Mean was calculated using the ANCOVA model with treatment, baseline value, and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors.

    Time frame: Baseline, Week 16

  12. Percentage of Participants Achieving ≥4-point Improvement in DLQI From Baseline to Week 16

    The DLQI is a 10-item, validated questionnaire used to assess the impact of skin disease on the quality of life of an affected person. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment, over the previous week. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". Questions are scored from 0 to 3, giving a possible total score range from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life). A high score is indicative of a poor quality of life.

    Time frame: Baseline to Week 16

  13. Percentage of Participants With a DLQI Total Score of ≥4-point at Baseline Achieving ≥4-point Improvement in DLQI From Baseline to Week 16

    The DLQI is a 10-item, validated questionnaire used to assess the impact of skin disease on the quality of life of an affected person. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment, over the previous week. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". Questions are scored from 0 to 3, giving a possible total score range from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life). A high score is indicative of a poor quality of life.

    Time frame: Baseline to Week 16

  14. Percentage Change in Sleep-loss Score From Baseline to Week 16

    Sleep Loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all)\]. Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant using an electronic diary. LS Mean was calculated using ANCOVA model with treatment, baseline value, and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors.

    Time frame: Baseline, Week 16

  15. Change From Baseline in Sleep-loss Score at Week 16

    Sleep Loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all)\]. Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant using an electronic diary. LS Mean was calculated using ANCOVA model with treatment, baseline value, and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors.

    Time frame: Baseline, Week 16

  16. Percentage of Participants With a Sleep-loss Score ≥2 Points at Baseline Who Achieve a ≥2 Points Reduction From Baseline to Week 16

    Sleep Loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all)\]. Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant using an electronic diary.

    Time frame: Baseline to Week 16

  17. Percentage of Participants With a Pruritus NRS Score of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 1

    Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

    Time frame: Baseline to Week 1

  18. Percentage of Participants With a Pruritus NRS Score of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 2

    Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

    Time frame: Baseline to Week 2

  19. Percentage of Participants With a Pruritus NRS Score of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 4

    Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

    Time frame: Baseline to Week 4

  20. Percentage of Participants With a Pruritus NRS Score of ≥5 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 1

    Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

    Time frame: Baseline to Week 1

  21. Percentage of Participants With a Pruritus NRS Score of ≥5 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 2

    Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

    Time frame: Baseline to Week 2

  22. Percentage of Participants With a Pruritus NRS Score of ≥5 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 4

    Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

    Time frame: Baseline to Week 4

  23. Percentage Change in SCORing Atopic Dermatitis (SCORAD) From Baseline to Week 16

    SCORAD is validated tool for assessing the extent and intensity of AD, it consists of 3 components: A=extent of AD as a percentage of each defined body area and reported as sum of all areas, with maximum score of 100%. B=severity of 6 specific symptoms of AD (redness, swelling, oozing/crusting, excoriation, skin thickening/lichenification, dryness) assessed using following scale: none=0, mild=1, moderate=2, or severe=3 for maximum of 18 total points. C=subjective assessment of itch and sleeplessness recorded by participant on visual analog scale (VAS), where 0=no itch/no sleeplessness and 10=worst imaginable itch/sleeplessness with maximum score of 20. SCORAD total score is calculated: A/5+7\*B/2+ C to give total score range of 0 to 103, where 0=no disease to 103=severe disease. LS Mean was calculated using ANCOVA model with treatment group and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.

    Time frame: Baseline, Week 16

  24. Pharmacokinetics (PK): Trough Serum Concentrations of Lebrikizumab in Maintenance Period (C-trough)

    C-trough was the concentration of study drug in the blood immediately before the next dose was administered. Trough serum concentration of Lebrikizumab was assessed at predose week 52.

    Time frame: Predose at Week 52

  25. Percentage of Participants From Those Re-randomized Having Achieved EASI-75 at Week 16 Who Continue to Exhibit EASI-75 at Week 52 (EASI-75 Calculated Relative to Baseline EASI Score)

    The EASI assesses objective physician estimates of 2 dimensions of AD - disease extent, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI-75 score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe). The EASI-75 responder is defined as a participant who achieves a ≥ 75% reduction from baseline in the EASI score.

    Time frame: Baseline to Week 52

  26. Percentage of Participants From Those Re-randomized Having Achieved IGA 0 or 1 and a ≥2-point Improvement From Baseline at Week 16 Who Continue to Exhibit an IGA 0 or 1 and a ≥2-point Improvement From Baseline at Week 52

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

    Time frame: Baseline to Week 52

  27. Percentage of Participants From Those With a Pruritus NRS of ≥4-points at Baseline Re-randomized Having Achieved ≥4-point Reduction From Baseline at Week 16 Who Continue to Exhibit ≥4-point Reduction From Baseline at Week 52

    Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

    Time frame: Baseline to Week 52

  28. Percentage of Participants From Those With a Pruritus NRS of ≥5-points at Baseline Re-randomized Having Achieved ≥4-point Reduction From Baseline at Week 16 Who Continue to Exhibit ≥4-point Reduction From Baseline at Week 52

    Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

    Time frame: Baseline to Week 52

  29. Percentage Change in SCORAD (From Those Re-randomized Having Achieved EASI-75 at Week 16) From Baseline at Week 52

    SCORAD is a validated tool for assessing the extent and intensity of AD, it consists of 3 components: A=extent of AD as a percentage of each defined body area and reported as sum of all areas, with maximum score of 100%. B=severity of 6 specific symptoms of AD (redness, swelling, oozing/crusting, excoriation, skin thickening/lichenification, dryness) assessed using following scale: none=0, mild=1, moderate=2, or severe=3 for maximum of 18 total points. C=subjective assessment of itch and sleeplessness recorded by participant on VAS, where 0=no itch/no sleeplessness and 10=worst imaginable itch/sleeplessness with maximum score of 20. SCORAD total score is calculated: A/5+7\*B/2+ C to give total score range of 0 to 103, where 0=no disease to 103=severe disease. LS Mean was calculated using ANCOVA model with treatment group and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.

    Time frame: Baseline, Week 52

  30. Change From Baseline in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) at Week 16 - Health State Index

    The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a is a 2-part questionnaire which measure health status of the participant. The first component (Health state) is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.

    Time frame: Baseline, Week 16

  31. Change From Baseline in EQ-5D-5L at Week 16 - Visual Analog Scale (VAS)

    The EQ-5D-5L is a 2-part measurement. The second part is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.

    Time frame: Baseline, Week 16

  32. Change From Baseline in Patient Oriented Eczema Measure (POEM) at Week 16

    POEM is a 7-item, validated, questionnaire used by the participant to assess disease symptoms over the last week. The participant is asked to respond to 7 questions on skin dryness, itching, flaking, cracking, sleep loss, bleeding and weeping. All 7 answers carry equal weight with a total possible score from 0 to 28 (answers scored as: No days=0; 1-2 days = 1; 3-4 days = 2; 5-6 days = 3; everyday = 4). A high score is indicative of a poor quality of life. POEM responses will be captured using an electronic diary and transferred into the clinical database. LS Mean was calculated using MMRM model using treatment, baseline value, visit, the interaction of the baseline value-by-visit, the interaction of treatment by-visit as covariates, geographic region, age group, baseline IGA (3 versus 4) score as fixed.

    Time frame: Baseline, Week 16

  33. Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety at Week 16-Adolescents

    PROMIS® is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Participants ≤17 years will complete pediatric versions for the duration of the study. PROMIS anxiety has 8 questions on Emotion Distress-Anxiety (or Pediatric Anxiety Symptom). Each question has 5 response options with values from 1 to 5. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater anxiety. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.

    Time frame: Baseline, Week 16

  34. Change From Baseline in PROMIS Anxiety at Week 16 - Adults

    PROMIS® is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Participants ≤17 years will complete pediatric versions for the duration of the study. PROMIS anxiety has 8 questions on Emotion Distress-Anxiety (or Pediatric Anxiety Symptom). Each question has 5 response options with values from 1 to 5. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater anxiety. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.

    Time frame: Baseline, Week 16

  35. Change From Baseline in PROMIS Depression at Week 16- Adolescents

    PROMIS® is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Participants ≤17 years will complete pediatric versions for the duration of the study. PROMIS anxiety has 8 questions on Emotion Distress-Anxiety (or Pediatric Anxiety Symptom). Each question has 5 response options with values from 1 to 5. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater anxiety. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.

    Time frame: Baseline, Week 16

  36. Change From Baseline in PROMIS Depression at Week 16- Adults

    PROMIS® is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Participants ≤17 years will complete pediatric versions for the duration of the study. PROMIS anxiety has 8 questions on Emotion Distress-Anxiety (or Pediatric Anxiety Symptom). Each question has 5 response options with values from 1 to 5. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater anxiety. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.

    Time frame: Baseline, Week 16

  37. Change From Baseline in Asthma Control Questionnaire (ACQ-5) Score at Week 16 in Participants Who Have Self-reported Comorbid Asthma

    The ACQ-5 is a five-item, self-completed questionnaire, which is used as a measure of asthma control of a participant. The five questions (concerning nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheeze) enquire about the frequency and/or severity of symptoms over the previous week. The response options for all these questions range from zero (no impairment/limitation) to six (total impairment/ limitation) scale. The ACQ-5 score is the average of the individual item scores and ranges from 0 (totally controlled) to 6 (severely uncontrolled). Higher scores indicate lower asthma control. LS Mean was calculated using ANCOVA with treatment, geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.

    Time frame: Baseline, Week 16

  38. Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 16

    The CDLQI questionnaire is designed for use in children (4 to 16 years of age). It consists of 10 items that are grouped into 6 domains: symptoms \& feelings, leisure, school or holidays, personal relationships, sleep, \& treatment. The scoring of each question is: Very much =3; Quite a lot = 2; Only a little = 1; Not at all = 0. CDLQI total score is calculated by summing all 10 items responses, and has a range of 0 to 30 (higher scores are indicative of greater impairment). LS Mean was calculated using MMRM model which includes treatment, baseline value, visit, the interaction of the baseline value-by-visit as covariates, the interaction of treatment by-visit, geographic region, age group, and baseline IGA (3 versus 4) score as fixed factors.

    Time frame: Baseline, Week 16

07

Results

Posted Sep 16, 2022
Limitations and caveats
One investigational site with eighteen participants was excluded from analysis due to GCP issues.

Participant flow

During the Induction period (16-weeks): Participants were randomly assigned to either 250 mg lebrikizumab Q2W or placebo; At week 16, participants who responded to treatment, defined as having an Investigator Global Assessment (IGA) of 0 or 1 or a 75% reduction in Eczema Area and Severity Index (EASI-75) from Baseline to Week 16 entered Maintenance Period and were re-randomized (2:2:1) to: lebrikizumab 250 mg Q2W, lebrikizumab 250 mg Q4W, or placebo (Continued)

Induction Period
Participant flow — Induction Period
MilestoneInduction - PlaceboInduction - Lebrikizumab Q2WMaintenance Blinded Treatment - Placebo Responder/Placebo (PBO)Maintenance Blinded Treatment - Placebo Responder/Lebrikizumab 250 Q4WMaintenance Blinded Treatment - Placebo Responder/Lebrikizumab 250 Q2WMaintenance Blinded Treatment - Lebrikizumab Responder/PlaceboMaintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q4WMaintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q2WEscape Arm Week 16 - Maintenance Open Label - Placebo Nonresponder/ Lebrikizumab 250 Q2WEscape Arm Week 16 - Maintenance Open Label - Lebrikizumab Nonresponder/ Lebrikizumab 250 Q2WEscape Arm Week 24 to 48 - Maintenance Open Label Lebrikizumab 250 Q2W
Started150295000000000
Received at least one dose of study drug149295000000000
Completed133273000000000
Not completed1722000000000
Withdrew: Adverse event46000000000
Withdrew: Due to epidemic/pandemic14000000000
Withdrew: Lack of efficacy41000000000
Withdrew: Protocol violation06000000000
Withdrew: Withdrawal by subject64000000000
Withdrew: Lost to follow-up20000000000
Withdrew: Participant missed study visits01000000000
Maintenance Blinded Treatment Period
Participant flow — Maintenance Blinded Treatment Period
MilestoneInduction - PlaceboInduction - Lebrikizumab Q2WMaintenance Blinded Treatment - Placebo Responder/Placebo (PBO)Maintenance Blinded Treatment - Placebo Responder/Lebrikizumab 250 Q4WMaintenance Blinded Treatment - Placebo Responder/Lebrikizumab 250 Q2WMaintenance Blinded Treatment - Lebrikizumab Responder/PlaceboMaintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q4WMaintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q2WEscape Arm Week 16 - Maintenance Open Label - Placebo Nonresponder/ Lebrikizumab 250 Q2WEscape Arm Week 16 - Maintenance Open Label - Lebrikizumab Nonresponder/ Lebrikizumab 250 Q2WEscape Arm Week 24 to 48 - Maintenance Open Label Lebrikizumab 250 Q2W
Started005911305959000
Received at least one dose of study drug005911305959000
Completed00469225142000
Not completed001328817000
Withdrew: Adverse event00000121000
Withdrew: Lack of efficacy00000100000
Withdrew: Lost to follow-up00010000000
Withdrew: Physician decision00000010000
Withdrew: Withdrawal by subject00001204000
Withdrew: Sponsor decision00111146000
Withdrew: Entered escape arm00010316000
Maintenance Open Label Escape Arm
Participant flow — Maintenance Open Label Escape Arm
MilestoneInduction - PlaceboInduction - Lebrikizumab Q2WMaintenance Blinded Treatment - Placebo Responder/Placebo (PBO)Maintenance Blinded Treatment - Placebo Responder/Lebrikizumab 250 Q4WMaintenance Blinded Treatment - Placebo Responder/Lebrikizumab 250 Q2WMaintenance Blinded Treatment - Lebrikizumab Responder/PlaceboMaintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q4WMaintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q2WEscape Arm Week 16 - Maintenance Open Label - Placebo Nonresponder/ Lebrikizumab 250 Q2WEscape Arm Week 16 - Maintenance Open Label - Lebrikizumab Nonresponder/ Lebrikizumab 250 Q2WEscape Arm Week 24 to 48 - Maintenance Open Label Lebrikizumab 250 Q2W
Started0000000010812511
Received at least one dose of study drug0000000010812511
Completed0000000085838
Not completed0000000023423
Withdrew: Adverse event00000000330
Withdrew: Lack of efficacy0000000016272
Withdrew: Lost to follow-up00000000010
Withdrew: Withdrawal by subject00000000491
Withdrew: Sponsor decision00000000010
Withdrew: Participant missed study visits00000000010

Outcome measures

PrimaryPercentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16

The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16
percentage of participantsPlaceboLebrikizumab Q2W
Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 1610.8 (5.7 to 15.9)33.2 (27.5 to 38.9)
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · Cochran-Mantel-Haenszel · p = 0.000004 · Risk difference (rd): 21.9 · 95% CI 14.2 to 29.6
PrimaryPercentage of Participants Achieving Eczema Area And Severity Index (EASI-75) (≥75% Reduction in EASI Score) From Baseline to Week 16

The EASI assesses objective physician estimates of 2 dimensions of AD - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI-75 responder is defined as a participant who achieves a ≥ 75% reduction from baseline in the EASI score.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Eczema Area And Severity Index (EASI-75) (≥75% Reduction in EASI Score) From Baseline to Week 16
percentage of participantsPlaceboLebrikizumab Q2W
Percentage of Participants Achieving Eczema Area And Severity Index (EASI-75) (≥75% Reduction in EASI Score) From Baseline to Week 1618.1 (11.7 to 24.5)52.1 (46.1 to 58.0)
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · Cochran-Mantel-Haenszel · p = <0.000001 · Risk difference (rd): 33.3 · 95% CI 24.4 to 42.2
SecondaryPercentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 2

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

Time frame:
Baseline to Week 2
Reported as:
Number · percentage of participants
Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 2
percentage of participantsPlaceboLebrikizumab Q2W
Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 20 (0.0 to 0.0)0.7 (-0.3 to 1.7)
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · Cochran-Mantel-Haenszel · p = 0.308463 · Risk difference (rd): 0.7 · 95% CI -0.3 to 1.7
SecondaryPercentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 4

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

Time frame:
Baseline to Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 4
percentage of participantsPlaceboLebrikizumab Q2W
Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 41.4 (0.0 to 3.3)9.0 (5.6 to 12.4)
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · Cochran-Mantel-Haenszel · p = 0.001607 · Risk difference (rd): 8.1 · 95% CI 4.1 to 12.0
SecondaryPercentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16
percentage of participantsPlaceboLebrikizumab Q2W
Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 1610.8 (5.7 to 15.9)33.2 (27.5 to 38.9)
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · Cochran-Mantel-Haenszel · p = 0.000004 · Risk difference (rd): 21.9 · 95% CI 14.2 to 29.6
SecondaryPercentage of Participants Achieving EASI-90 (≥90% Reduction in EASI Score) From Baseline to Week 16

The EASI assesses objective physician estimates of 2 dimensions of AD - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI-90 responder is defined as a participant who achieves a ≥ 90% reduction from baseline in the EASI score.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving EASI-90 (≥90% Reduction in EASI Score) From Baseline to Week 16
percentage of participantsPlaceboLebrikizumab Q2W
Percentage of Participants Achieving EASI-90 (≥90% Reduction in EASI Score) From Baseline to Week 169.5 (4.6 to 14.3)30.7 (25.2 to 36.2)
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · Cochran-Mantel-Haenszel · p = 0.000008 · Risk difference (rd): 20.7 · 95% CI 13.3 to 28.1
SecondaryPercentage Change in Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable." Least Squares (LS) Mean was calculated using analysis of covariance (ANCOVA) model with treatment and randomization strata (region, disease severity, age) as fixed factors and baseline value as covariate.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · percentage change
Percentage Change in Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16
percentage changePlaceboLebrikizumab Q2W
Percentage Change in Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16-9.02 ± 3.868-36.56 ± 3.321
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · ANCOVA · p = <0.000001 · Ls mean difference (final values): -27.53 · 95% CI -34.9 to -20.2
SecondaryPercentage of Participants With a Pruritus NRS Score of ≥4-points at Baseline Who Achieve a ≥4-point Reduction in Pruritus NRS Score From Baseline to Week 16

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Pruritus NRS Score of ≥4-points at Baseline Who Achieve a ≥4-point Reduction in Pruritus NRS Score From Baseline to Week 16
percentage of participantsPlaceboLebrikizumab Q2W
Percentage of Participants With a Pruritus NRS Score of ≥4-points at Baseline Who Achieve a ≥4-point Reduction in Pruritus NRS Score From Baseline to Week 1611.5 (6.0 to 16.9)39.8 (33.6 to 46.0)
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · Cochran-Mantel-Haenszel · p = <0.000001 · Risk difference (rd): 28.3 · 95% CI 20.0 to 36.5
SecondaryPercentage of Participants With a Pruritus NRS Score of ≥5-points at Baseline Who Achieve a ≥4-point Reduction in Pruritus NRS Score From Baseline to Week 16

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Pruritus NRS Score of ≥5-points at Baseline Who Achieve a ≥4-point Reduction in Pruritus NRS Score From Baseline to Week 16
percentage of participantsPlaceboLebrikizumab Q2W
Percentage of Participants With a Pruritus NRS Score of ≥5-points at Baseline Who Achieve a ≥4-point Reduction in Pruritus NRS Score From Baseline to Week 1611.8 (6.0 to 17.6)41.6 (35.1 to 48.1)
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · Cochran-Mantel-Haenszel · p = <0.000001 · Risk difference (rd): 29.7 · 95% CI 21.0 to 38.4
SecondaryPercentage Change in EASI Score From Baseline to Week 16

The EASI assesses objective physician estimates of 2 dimensions of AD - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). LS Mean was calculated using ANCOVA model with treatment, stratification factors of geographic region, age group, baseline IGA score (IGA 3 versus 4) as fixed factors baseline value as covariate.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · percent change
Percentage Change in EASI Score From Baseline to Week 16
percent changePlaceboLebrikizumab Q2W
Percentage Change in EASI Score From Baseline to Week 16-27.96 ± 3.893-61.53 ± 3.300
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · ANCOVA · p = <0.000001 · Ls mean difference (final values): -33.57 · 95% CI -41.2 to -26.0
SecondaryChange From Baseline in Percent Body Surface Area (BSA) at Week 16

The BSA affected by AD will be assessed for 4 separate body regions: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region will be assessed for disease extent ranging from 0% to 100% involvement. BSA was calculated using the participant's palm using the 1% rule, 1 palm was equivalent to 1% with estimates of the number of palms it takes to cover the affected AD area. Maximum number of palms were 10 palms for head and neck (10%), 20 palms for upper extremities (20%), 30 palms for trunk, including axilla and groin (30%), 40 palms for lower extremities, including buttocks (40%). Percent of BSA for a body region was calculated as = total number of palms in a body region \* % surface area equivalent to 1 palm. Overall percent BSA of all 4 body regions ranges from 0% to 100 % with higher values representing greater severity of AD.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · percentage of BSA
Change From Baseline in Percent Body Surface Area (BSA) at Week 16
percentage of BSAPlaceboLebrikizumab Q2W
Change From Baseline in Percent Body Surface Area (BSA) at Week 16-14.0 ± 1.94-30.2 ± 1.33
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · Mixed Models Analysis · p = <0.000001 · Ls mean difference (final values): -16.2 · 95% CI -20.3 to -12.0
SecondaryPercentage of Participants Achieving EASI-90 From Baseline to Week 4

The EASI assesses objective physician estimates of 2 dimensions of AD - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI-90 responder is defined as a participant who achieves a ≥ 90% reduction from baseline in the EASI score.

Time frame:
Baseline to Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Achieving EASI-90 From Baseline to Week 4
percentage of participantsPlaceboLebrikizumab Q2W
Percentage of Participants Achieving EASI-90 From Baseline to Week 41.5 (-0.5 to 3.5)6.3 (3.4 to 9.2)
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · Cochran-Mantel-Haenszel · p = 0.022921 · Risk difference (rd): 4.9 · 95% CI 1.4 to 8.4
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) at Week 16

The DLQI is a 10-item, validated questionnaire used to assess the impact of skin disease on the quality of life of an affected person. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment, over the previous week. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". Questions are scored from 0 to 3, giving a possible total score range from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life). A high score is indicative of a poor quality of life. LS Mean was calculated using the ANCOVA model with treatment, baseline value, and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16
score on a scalePlaceboLebrikizumab Q2W
Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16-2.4 ± 1.17-7.3 ± 1.16
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · ANCOVA · p = <0.000001 · Ls mean difference (final values): -4.9 · 95% CI -6.3 to -3.5
SecondaryPercentage of Participants Achieving ≥4-point Improvement in DLQI From Baseline to Week 16

The DLQI is a 10-item, validated questionnaire used to assess the impact of skin disease on the quality of life of an affected person. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment, over the previous week. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". Questions are scored from 0 to 3, giving a possible total score range from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life). A high score is indicative of a poor quality of life.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥4-point Improvement in DLQI From Baseline to Week 16
percentage of participantsPlaceboLebrikizumab Q2W
Percentage of Participants Achieving ≥4-point Improvement in DLQI From Baseline to Week 1632.8 (24.1 to 41.4)65.4 (59.0 to 71.9)
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · Cochran-Mantel-Haenszel · p = 0.000001 · Risk difference (rd): 32.9 · 95% CI 22.2 to 43.6
SecondaryPercentage of Participants With a DLQI Total Score of ≥4-point at Baseline Achieving ≥4-point Improvement in DLQI From Baseline to Week 16

The DLQI is a 10-item, validated questionnaire used to assess the impact of skin disease on the quality of life of an affected person. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment, over the previous week. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". Questions are scored from 0 to 3, giving a possible total score range from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life). A high score is indicative of a poor quality of life.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a DLQI Total Score of ≥4-point at Baseline Achieving ≥4-point Improvement in DLQI From Baseline to Week 16
percentage of participantsPlaceboLebrikizumab Q2W
Percentage of Participants With a DLQI Total Score of ≥4-point at Baseline Achieving ≥4-point Improvement in DLQI From Baseline to Week 1633.6 (24.8 to 42.5)66.3 (59.9 to 72.8)
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · Cochran-Mantel-Haenszel · p = 0.000001 · Risk difference (rd): 33.0 · 95% CI 22.2 to 43.8
SecondaryPercentage Change in Sleep-loss Score From Baseline to Week 16

Sleep Loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all)\]. Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant using an electronic diary. LS Mean was calculated using ANCOVA model with treatment, baseline value, and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · percent change
Percentage Change in Sleep-loss Score From Baseline to Week 16
percent changePlaceboLebrikizumab Q2W
Percentage Change in Sleep-loss Score From Baseline to Week 16-11.29 ± 5.393-48.37 ± 4.590
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · ANCOVA · p = <0.000001 · Ls mean difference (final values): -37.09 · 95% CI -47.4 to -26.8
SecondaryChange From Baseline in Sleep-loss Score at Week 16

Sleep Loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all)\]. Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant using an electronic diary. LS Mean was calculated using ANCOVA model with treatment, baseline value, and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Sleep-loss Score at Week 16
score on a scalePlaceboLebrikizumab Q2W
Change From Baseline in Sleep-loss Score at Week 16-0.35 ± 0.095-1.05 ± 0.080
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · ANCOVA · p = <0.000001 · Ls mean difference (final values): -0.70 · 95% CI -0.9 to -0.5
SecondaryPercentage of Participants With a Sleep-loss Score ≥2 Points at Baseline Who Achieve a ≥2 Points Reduction From Baseline to Week 16

Sleep Loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all)\]. Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant using an electronic diary.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Sleep-loss Score ≥2 Points at Baseline Who Achieve a ≥2 Points Reduction From Baseline to Week 16
percentage of participantsPlaceboLebrikizumab Q2W
Percentage of Participants With a Sleep-loss Score ≥2 Points at Baseline Who Achieve a ≥2 Points Reduction From Baseline to Week 168.2 (2.5 to 13.9)28.0 (21.0 to 35.0)
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · Cochran-Mantel-Haenszel · p = 0.000571 · Risk difference (rd): 18.9 · 95% CI 9.6 to 28.1
SecondaryPercentage of Participants With a Pruritus NRS Score of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 1

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

Time frame:
Baseline to Week 1
Reported as:
Number · percentage of participants
Percentage of Participants With a Pruritus NRS Score of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 1
percentage of participantsPlaceboLebrikizumab Q2W
Percentage of Participants With a Pruritus NRS Score of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 10.0 (0.0 to 0.0)0.4 (0.0 to 1.2)
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · Cochran-Mantel-Haenszel · p = 0.469221 · Risk difference (rd): 0.4 · 95% CI -0.4 to 1.2
SecondaryPercentage of Participants With a Pruritus NRS Score of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 2

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

Time frame:
Baseline to Week 2
Reported as:
Number · percentage of participants
Percentage of Participants With a Pruritus NRS Score of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 2
percentage of participantsPlaceboLebrikizumab Q2W
Percentage of Participants With a Pruritus NRS Score of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 20.7 (0.0 to 2.2)3.6 (1.3 to 5.9)
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · Cochran-Mantel-Haenszel · p = 0.113194 · Risk difference (rd): 2.7 · 95% CI -0.1 to 5.4
SecondaryPercentage of Participants With a Pruritus NRS Score of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 4

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

Time frame:
Baseline to Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With a Pruritus NRS Score of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 4
percentage of participantsPlaceboLebrikizumab Q2W
Percentage of Participants With a Pruritus NRS Score of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 43.0 (0.1 to 6.0)16.8 (12.2 to 21.4)
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · Cochran-Mantel-Haenszel · p = 0.000230 · Risk difference (rd): 13.2 · 95% CI 7.7 to 18.7
SecondaryPercentage of Participants With a Pruritus NRS Score of ≥5 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 1

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

Time frame:
Baseline to Week 1
Reported as:
Number · percentage of participants
Percentage of Participants With a Pruritus NRS Score of ≥5 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 1
percentage of participantsPlaceboLebrikizumab Q2W
Percentage of Participants With a Pruritus NRS Score of ≥5 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 10.0 (0.0 to 0.0)0.4 (0.0 to 1.3)
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · Cochran-Mantel-Haenszel · p = 0.468160 · Risk difference (rd): 0.4 · 95% CI -0.4 to 1.3
SecondaryPercentage of Participants With a Pruritus NRS Score of ≥5 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 2

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

Time frame:
Baseline to Week 2
Reported as:
Number · percentage of participants
Percentage of Participants With a Pruritus NRS Score of ≥5 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 2
percentage of participantsPlaceboLebrikizumab Q2W
Percentage of Participants With a Pruritus NRS Score of ≥5 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 20.8 (0.0 to 2.4)3.9 (1.4 to 6.3)
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · Cochran-Mantel-Haenszel · p = 0.115770 · Risk difference (rd): 2.9 · 95% CI -0.1 to 5.8
SecondaryPercentage of Participants With a Pruritus NRS Score of ≥5 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 4

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

Time frame:
Baseline to Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With a Pruritus NRS Score of ≥5 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 4
percentage of participantsPlaceboLebrikizumab Q2W
Percentage of Participants With a Pruritus NRS Score of ≥5 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 43.3 (0.1 to 6.6)18.1 (13.2 to 23.1)
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · Cochran-Mantel-Haenszel · p = 0.000252 · Risk difference (rd): 14.2 · 95% CI 8.2 to 20.1
SecondaryPercentage Change in SCORing Atopic Dermatitis (SCORAD) From Baseline to Week 16

SCORAD is validated tool for assessing the extent and intensity of AD, it consists of 3 components: A=extent of AD as a percentage of each defined body area and reported as sum of all areas, with maximum score of 100%. B=severity of 6 specific symptoms of AD (redness, swelling, oozing/crusting, excoriation, skin thickening/lichenification, dryness) assessed using following scale: none=0, mild=1, moderate=2, or severe=3 for maximum of 18 total points. C=subjective assessment of itch and sleeplessness recorded by participant on visual analog scale (VAS), where 0=no itch/no sleeplessness and 10=worst imaginable itch/sleeplessness with maximum score of 20. SCORAD total score is calculated: A/5+7\*B/2+ C to give total score range of 0 to 103, where 0=no disease to 103=severe disease. LS Mean was calculated using ANCOVA model with treatment group and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · percent change
Percentage Change in SCORing Atopic Dermatitis (SCORAD) From Baseline to Week 16
percent changePlaceboLebrikizumab Q2W
Percentage Change in SCORing Atopic Dermatitis (SCORAD) From Baseline to Week 16-13.81 ± 3.197-44.57 ± 2.677
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · ANCOVA · p = <0.000001 · Ls mean difference (final values): -30.76 · 95% CI -36.93 to -24.59
SecondaryPharmacokinetics (PK): Trough Serum Concentrations of Lebrikizumab in Maintenance Period (C-trough)

C-trough was the concentration of study drug in the blood immediately before the next dose was administered. Trough serum concentration of Lebrikizumab was assessed at predose week 52.

Time frame:
Predose at Week 52
Reported as:
Mean · micrograms/milliliter (µg/mL)
Pharmacokinetics (PK): Trough Serum Concentrations of Lebrikizumab in Maintenance Period (C-trough)
micrograms/milliliter (µg/mL)Maintenance 250 mg Lebrikizumab Q4WMaintenance 250 mg Lebrikizumab Q2W and 250 mg Lebrikizumab Escape Q2W
Pharmacokinetics (PK): Trough Serum Concentrations of Lebrikizumab in Maintenance Period (C-trough)46.7 ± 24.890.5 ± 40.1
SecondaryPercentage of Participants From Those Re-randomized Having Achieved EASI-75 at Week 16 Who Continue to Exhibit EASI-75 at Week 52 (EASI-75 Calculated Relative to Baseline EASI Score)

The EASI assesses objective physician estimates of 2 dimensions of AD - disease extent, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI-75 score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe). The EASI-75 responder is defined as a participant who achieves a ≥ 75% reduction from baseline in the EASI score.

Time frame:
Baseline to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants From Those Re-randomized Having Achieved EASI-75 at Week 16 Who Continue to Exhibit EASI-75 at Week 52 (EASI-75 Calculated Relative to Baseline EASI Score)
percentage of participantsMaintenance Blinded Treatment - Lebrikizumab Responder/PlaceboMaintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q4WMaintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q2W
Percentage of Participants From Those Re-randomized Having Achieved EASI-75 at Week 16 Who Continue to Exhibit EASI-75 at Week 52 (EASI-75 Calculated Relative to Baseline EASI Score)72.0 (53.0 to 91.0)84.7 (73.0 to 96.4)77.4 (65.4 to 89.4)
Statistical analysis
  • Maintenance Blinded Treatment - Lebrikizumab Responder/Placebo vs Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q4W · Cochran-Mantel-Haenszel · p = 0.238245 · Risk difference (rd): 12.8 · 95% CI -9.5 to 35.1
  • Maintenance Blinded Treatment - Lebrikizumab Responder/Placebo vs Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q2W · Cochran-Mantel-Haenszel · p = 0.612427 · Risk difference (rd): 4.8 · 95% CI -17.8 to 27.3
SecondaryPercentage of Participants From Those Re-randomized Having Achieved IGA 0 or 1 and a ≥2-point Improvement From Baseline at Week 16 Who Continue to Exhibit an IGA 0 or 1 and a ≥2-point Improvement From Baseline at Week 52

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

Time frame:
Baseline to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants From Those Re-randomized Having Achieved IGA 0 or 1 and a ≥2-point Improvement From Baseline at Week 16 Who Continue to Exhibit an IGA 0 or 1 and a ≥2-point Improvement From Baseline at Week 52
percentage of participantsMaintenance Blinded Treatment - Lebrikizumab Responder/PlaceboMaintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q4WMaintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q2W
Percentage of Participants From Those Re-randomized Having Achieved IGA 0 or 1 and a ≥2-point Improvement From Baseline at Week 16 Who Continue to Exhibit an IGA 0 or 1 and a ≥2-point Improvement From Baseline at Week 5249.8 (23.7 to 75.8)80.6 (65.9 to 95.3)64.6 (47.2 to 82.0)
Statistical analysis
  • Maintenance Blinded Treatment - Lebrikizumab Responder/Placebo vs Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q4W · Cochran-Mantel-Haenszel · p = 0.033876 · Risk difference (rd): 32.6 · 95% CI 2.6 to 62.5
  • Maintenance Blinded Treatment - Lebrikizumab Responder/Placebo vs Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q2W · Cochran-Mantel-Haenszel · p = 0.407417 · Risk difference (rd): 13.4 · 95% CI -17.5 to 44.3
SecondaryPercentage of Participants From Those With a Pruritus NRS of ≥4-points at Baseline Re-randomized Having Achieved ≥4-point Reduction From Baseline at Week 16 Who Continue to Exhibit ≥4-point Reduction From Baseline at Week 52

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

Time frame:
Baseline to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants From Those With a Pruritus NRS of ≥4-points at Baseline Re-randomized Having Achieved ≥4-point Reduction From Baseline at Week 16 Who Continue to Exhibit ≥4-point Reduction From Baseline at Week 52
percentage of participantsMaintenance Blinded Treatment - Lebrikizumab Responder/PlaceboMaintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q4WMaintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q2W
Percentage of Participants From Those With a Pruritus NRS of ≥4-points at Baseline Re-randomized Having Achieved ≥4-point Reduction From Baseline at Week 16 Who Continue to Exhibit ≥4-point Reduction From Baseline at Week 5267.6 (38.6 to 96.7)88.1 (77.1 to 99.1)90.3 (77.3 to 103.2)
Statistical analysis
  • Maintenance Blinded Treatment - Lebrikizumab Responder/Placebo vs Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q4W · Cochran-Mantel-Haenszel · p = 0.159281 · Risk difference (rd): 20.3 · 95% CI -11.4 to 52.0
  • Maintenance Blinded Treatment - Lebrikizumab Responder/Placebo vs Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q2W · Cochran-Mantel-Haenszel · p = 0.164950 · Risk difference (rd): 20.4 · 95% CI -10.6 to 51.4
SecondaryPercentage of Participants From Those With a Pruritus NRS of ≥5-points at Baseline Re-randomized Having Achieved ≥4-point Reduction From Baseline at Week 16 Who Continue to Exhibit ≥4-point Reduction From Baseline at Week 52

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

Time frame:
Baseline to Week 52
Reported as:
Number · percentage of partcipants
Percentage of Participants From Those With a Pruritus NRS of ≥5-points at Baseline Re-randomized Having Achieved ≥4-point Reduction From Baseline at Week 16 Who Continue to Exhibit ≥4-point Reduction From Baseline at Week 52
percentage of partcipantsMaintenance Blinded Treatment - Lebrikizumab Responder/PlaceboMaintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q4WMaintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q2W
Percentage of Participants From Those With a Pruritus NRS of ≥5-points at Baseline Re-randomized Having Achieved ≥4-point Reduction From Baseline at Week 16 Who Continue to Exhibit ≥4-point Reduction From Baseline at Week 5267.6 (38.6 to 96.7)87.4 (75.8 to 99.0)94.4 (83.6 to 105.1)
Statistical analysis
  • Maintenance Blinded Treatment - Lebrikizumab Responder/Placebo vs Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q4W · Cochran-Mantel-Haenszel · p = 0.179704 · Risk difference (rd): 19.7 · 95% CI -12.2 to 51.2
  • Maintenance Blinded Treatment - Lebrikizumab Responder/Placebo vs Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q2W · Cochran-Mantel-Haenszel · p = 0.083080 · Risk difference (rd): 24.3 · 95% CI -6.5 to 55.1
SecondaryPercentage Change in SCORAD (From Those Re-randomized Having Achieved EASI-75 at Week 16) From Baseline at Week 52

SCORAD is a validated tool for assessing the extent and intensity of AD, it consists of 3 components: A=extent of AD as a percentage of each defined body area and reported as sum of all areas, with maximum score of 100%. B=severity of 6 specific symptoms of AD (redness, swelling, oozing/crusting, excoriation, skin thickening/lichenification, dryness) assessed using following scale: none=0, mild=1, moderate=2, or severe=3 for maximum of 18 total points. C=subjective assessment of itch and sleeplessness recorded by participant on VAS, where 0=no itch/no sleeplessness and 10=worst imaginable itch/sleeplessness with maximum score of 20. SCORAD total score is calculated: A/5+7\*B/2+ C to give total score range of 0 to 103, where 0=no disease to 103=severe disease. LS Mean was calculated using ANCOVA model with treatment group and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · percent change
Percentage Change in SCORAD (From Those Re-randomized Having Achieved EASI-75 at Week 16) From Baseline at Week 52
percent changeMaintenance Blinded Treatment - Lebrikizumab Responder/PlaceboMaintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q4WMaintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q2W
Percentage Change in SCORAD (From Those Re-randomized Having Achieved EASI-75 at Week 16) From Baseline at Week 52-67.60 ± 3.767-73.89 ± 2.718-73.85 ± 2.764
Statistical analysis
  • Maintenance Blinded Treatment - Lebrikizumab Responder/Placebo vs Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q4W · ANCOVA · p = 0.176748 · Ls mean difference (final values): -6.29 · 95% CI -15.46 to 2.87
  • Maintenance Blinded Treatment - Lebrikizumab Responder/Placebo vs Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q2W · ANCOVA · p = 0.183151 · Ls mean difference (final values): -6.25 · 95% CI -15.48 to 2.99
SecondaryChange From Baseline in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) at Week 16 - Health State Index

The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a is a 2-part questionnaire which measure health status of the participant. The first component (Health state) is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) at Week 16 - Health State Index
score on a scalePlaceboLebrikizumab Q2W
Health State Index UK0.0 ± 0.020.1 ± 0.02
Health State Index US0.0 ± 0.010.1 ± 0.01
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · ANCOVA · p = 0.000001 · Ls mean difference (final values): 0.1 · 95% CI 0.1 to 0.1
  • Placebo vs Lebrikizumab Q2W · ANCOVA · p = 0.000001 · Ls mean difference (final values): 0.1 · 95% CI 0.0 to 0.1
SecondaryChange From Baseline in EQ-5D-5L at Week 16 - Visual Analog Scale (VAS)

The EQ-5D-5L is a 2-part measurement. The second part is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · millimeters (mm)
Change From Baseline in EQ-5D-5L at Week 16 - Visual Analog Scale (VAS)
millimeters (mm)PlaceboLebrikizumab Q2W
Change From Baseline in EQ-5D-5L at Week 16 - Visual Analog Scale (VAS)5.2 ± 1.629.7 ± 1.36
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · ANCOVA · p = 0.005304 · Ls mean difference (final values): 4.5 · 95% CI 1.3 to 7.6
SecondaryChange From Baseline in Patient Oriented Eczema Measure (POEM) at Week 16

POEM is a 7-item, validated, questionnaire used by the participant to assess disease symptoms over the last week. The participant is asked to respond to 7 questions on skin dryness, itching, flaking, cracking, sleep loss, bleeding and weeping. All 7 answers carry equal weight with a total possible score from 0 to 28 (answers scored as: No days=0; 1-2 days = 1; 3-4 days = 2; 5-6 days = 3; everyday = 4). A high score is indicative of a poor quality of life. POEM responses will be captured using an electronic diary and transferred into the clinical database. LS Mean was calculated using MMRM model using treatment, baseline value, visit, the interaction of the baseline value-by-visit, the interaction of treatment by-visit as covariates, geographic region, age group, baseline IGA (3 versus 4) score as fixed.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Patient Oriented Eczema Measure (POEM) at Week 16
score on a scalePlaceboLebrikizumab Q2W
Change From Baseline in Patient Oriented Eczema Measure (POEM) at Week 16-3.5 ± 0.77-9.5 ± 0.52
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · Mixed Models Analysis · p = <0.000001 · Ls mean difference (final values): -6.0 · 95% CI -7.7 to -4.3
SecondaryChange From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety at Week 16-Adolescents

PROMIS® is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Participants ≤17 years will complete pediatric versions for the duration of the study. PROMIS anxiety has 8 questions on Emotion Distress-Anxiety (or Pediatric Anxiety Symptom). Each question has 5 response options with values from 1 to 5. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater anxiety. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · T-score
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety at Week 16-Adolescents
T-scorePlaceboLebrikizumab Q2W
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety at Week 16-Adolescents0.12 ± 2.129-2.79 ± 1.550
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · ANCOVA · p = 0.241275 · Ls mean difference (final values): -2.91 · 95% CI -7.85 to 2.03
SecondaryChange From Baseline in PROMIS Anxiety at Week 16 - Adults

PROMIS® is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Participants ≤17 years will complete pediatric versions for the duration of the study. PROMIS anxiety has 8 questions on Emotion Distress-Anxiety (or Pediatric Anxiety Symptom). Each question has 5 response options with values from 1 to 5. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater anxiety. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · T-score
Change From Baseline in PROMIS Anxiety at Week 16 - Adults
T-scorePlaceboLebrikizumab Q2W
Change From Baseline in PROMIS Anxiety at Week 16 - Adults-0.45 ± 0.580-3.18 ± 0.422
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · ANCOVA · p = 0.000116 · Ls mean difference (final values): -2.74 · 95% CI -4.12 to -1.36
SecondaryChange From Baseline in PROMIS Depression at Week 16- Adolescents

PROMIS® is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Participants ≤17 years will complete pediatric versions for the duration of the study. PROMIS anxiety has 8 questions on Emotion Distress-Anxiety (or Pediatric Anxiety Symptom). Each question has 5 response options with values from 1 to 5. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater anxiety. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · T-score
Change From Baseline in PROMIS Depression at Week 16- Adolescents
T-scorePlaceboLebrikizumab Q2W
Change From Baseline in PROMIS Depression at Week 16- Adolescents-0.57 ± 2.047-1.67 ± 1.493
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · ANCOVA · p = 0.645132 · Ls mean difference (final values): -1.10 · 95% CI -5.86 to 3.67
SecondaryChange From Baseline in PROMIS Depression at Week 16- Adults

PROMIS® is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Participants ≤17 years will complete pediatric versions for the duration of the study. PROMIS anxiety has 8 questions on Emotion Distress-Anxiety (or Pediatric Anxiety Symptom). Each question has 5 response options with values from 1 to 5. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater anxiety. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · T-score
Change From Baseline in PROMIS Depression at Week 16- Adults
T-scorePlaceboLebrikizumab Q2W
Change From Baseline in PROMIS Depression at Week 16- Adults0.16 ± 0.540-2.59 ± 0.392
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · ANCOVA · p = 0.000031 · Ls mean difference (final values): -2.75 · 95% CI -4.03 to -1.47
SecondaryChange From Baseline in Asthma Control Questionnaire (ACQ-5) Score at Week 16 in Participants Who Have Self-reported Comorbid Asthma

The ACQ-5 is a five-item, self-completed questionnaire, which is used as a measure of asthma control of a participant. The five questions (concerning nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheeze) enquire about the frequency and/or severity of symptoms over the previous week. The response options for all these questions range from zero (no impairment/limitation) to six (total impairment/ limitation) scale. The ACQ-5 score is the average of the individual item scores and ranges from 0 (totally controlled) to 6 (severely uncontrolled). Higher scores indicate lower asthma control. LS Mean was calculated using ANCOVA with treatment, geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Asthma Control Questionnaire (ACQ-5) Score at Week 16 in Participants Who Have Self-reported Comorbid Asthma
score on a scalePlaceboLebrikizumab Q2W
Change From Baseline in Asthma Control Questionnaire (ACQ-5) Score at Week 16 in Participants Who Have Self-reported Comorbid Asthma0.19 ± 0.1400.19 ± 0.108
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · ANCOVA · p = 0.974417 · Ls mean difference (final values): -0.00 · 95% CI -0.27 to 0.26
SecondaryChange From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 16

The CDLQI questionnaire is designed for use in children (4 to 16 years of age). It consists of 10 items that are grouped into 6 domains: symptoms \& feelings, leisure, school or holidays, personal relationships, sleep, \& treatment. The scoring of each question is: Very much =3; Quite a lot = 2; Only a little = 1; Not at all = 0. CDLQI total score is calculated by summing all 10 items responses, and has a range of 0 to 30 (higher scores are indicative of greater impairment). LS Mean was calculated using MMRM model which includes treatment, baseline value, visit, the interaction of the baseline value-by-visit as covariates, the interaction of treatment by-visit, geographic region, age group, and baseline IGA (3 versus 4) score as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 16
score on a scalePlaceboLebrikizumab Q2W
Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 16-3.4 ± 2.10-7.6 ± 1.13
Statistical analysis
  • Placebo vs Lebrikizumab Q2W · Mixed Models Analysis · p = 0.084769 · Ls mean difference (final values): -4.2 · 95% CI -9.1 to 0.6

Adverse events

Collected over Baseline up to Week 52. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Induction - Placebo1/149 (0.7%)4/149 (2.7%)97/149 (65.1%)
Induction - Lebrikizumab 250mg Q2W0/295 (0%)2/295 (0.7%)157/295 (53.2%)
Maintenance Blinded - Lebrikizumab Responder/ Placebo0/30 (0%)1/30 (3.3%)15/30 (50%)
Maintenance Blinded - Lebrikizumab Responder/Lebrikizumab Q4W0/59 (0%)0/59 (0%)32/59 (54.2%)
Maintenance Blinded - Lebrikizumab Responder/Lebrikizumab Q2W0/59 (0%)2/59 (3.4%)36/59 (61%)
Maintenance Blinded - Placebo Responder/ Placebo0/5 (0%)0/5 (0%)3/5 (60%)
Maintenance Blinded - Placebo Responder/Lebrikizumab Q4W0/9 (0%)2/9 (22.2%)4/9 (44.4%)
Maintenance Blinded - Placebo Responder/ Lebrikizumab Q2W0/11 (0%)0/11 (0%)8/11 (72.7%)
Escape Arm Week 16 - Maintenance Open Label (OL) -Placebo Non-Responder/Lebrikizumab Q2W0/108 (0%)1/108 (0.9%)68/108 (63%)
Escape Arm Week 16 - Maintenance OL- Lebrikizumab Non-Responder/Lebrikizumab Q2W1/125 (0.8%)5/125 (4%)77/125 (61.6%)
Escape Arm Week 24 to 48 - Maintenance Lebrikizumab0/11 (0%)0/11 (0%)5/11 (45.5%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventInduction - PlaceboInduction - Lebrikizumab 250mg Q2WMaintenance Blinded - Lebrikizumab Responder/ PlaceboMaintenance Blinded - Lebrikizumab Responder/Lebrikizumab Q4WMaintenance Blinded - Lebrikizumab Responder/Lebrikizumab Q2WMaintenance Blinded - Placebo Responder/ PlaceboMaintenance Blinded - Placebo Responder/Lebrikizumab Q4WMaintenance Blinded - Placebo Responder/ Lebrikizumab Q2WEscape Arm Week 16 - Maintenance Open Label (OL) -Placebo Non-Responder/Lebrikizumab Q2WEscape Arm Week 16 - Maintenance OL- Lebrikizumab Non-Responder/Lebrikizumab Q2WEscape Arm Week 24 to 48 - Maintenance Lebrikizumab
Hepatic steatosisHepatobiliary disorders0/1490/2950/300/590/590/51/90/110/1080/1250/11
Dermatitis atopicSkin and subcutaneous tissue disorders1/1491/2950/300/590/590/51/90/110/1082/1250/11
UreterolithiasisRenal and urinary disorders0/1490/2951/300/590/590/50/90/110/1080/1250/11
PancreatitisGastrointestinal disorders0/1490/2950/300/591/590/50/90/110/1080/1250/11
Humerus fractureInjury, poisoning and procedural complications0/1490/2950/300/591/590/50/90/110/1080/1250/11
Ulna fractureInjury, poisoning and procedural complications0/1490/2950/300/591/590/50/90/110/1080/1250/11
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/780/1470/150/340/330/30/70/60/540/550/3
Rhegmatogenous retinal detachmentEye disorders0/1490/2950/300/590/590/50/90/111/1080/1250/11
AcarodermatitisInfections and infestations0/1490/2950/300/590/590/50/90/110/1081/1250/11
ErysipelasInfections and infestations0/1490/2950/300/590/590/50/90/110/1081/1250/11
Most frequent other events
Showing 10 of 356
Most frequent other events
EventInduction - PlaceboInduction - Lebrikizumab 250mg Q2WMaintenance Blinded - Lebrikizumab Responder/ PlaceboMaintenance Blinded - Lebrikizumab Responder/Lebrikizumab Q4WMaintenance Blinded - Lebrikizumab Responder/Lebrikizumab Q2WMaintenance Blinded - Placebo Responder/ PlaceboMaintenance Blinded - Placebo Responder/Lebrikizumab Q4WMaintenance Blinded - Placebo Responder/ Lebrikizumab Q2WEscape Arm Week 16 - Maintenance Open Label (OL) -Placebo Non-Responder/Lebrikizumab Q2WEscape Arm Week 16 - Maintenance OL- Lebrikizumab Non-Responder/Lebrikizumab Q2WEscape Arm Week 24 to 48 - Maintenance Lebrikizumab
Dermatitis atopicSkin and subcutaneous tissue disorders38/14927/2953/303/593/590/50/90/113/1086/1252/11
Urinary tract infectionInfections and infestations1/1495/2950/303/593/591/50/90/112/1083/1251/11
Neck injuryInjury, poisoning and procedural complications0/1490/2950/300/590/591/50/90/110/1080/1250/11
Pain in extremityMusculoskeletal and connective tissue disorders1/1491/2950/300/590/591/50/90/110/1082/1250/11
HeadacheNervous system disorders8/14915/2951/303/592/591/51/90/113/1081/1250/11
NasopharyngitisInfections and infestations3/14915/2951/303/593/590/51/92/116/10810/1251/11
HypercholesterolaemiaMetabolism and nutrition disorders1/1490/2950/300/590/590/50/92/111/1080/1250/11
AsthmaRespiratory, thoracic and mediastinal disorders0/1491/2950/301/590/590/50/90/111/1081/1252/11
ThrombocytosisBlood and lymphatic system disorders0/1490/2950/300/590/590/51/90/110/1080/1250/11
Conjunctivitis allergicEye disorders2/1497/2951/304/591/590/50/91/1112/1081/1250/11

Baseline characteristics

All randomized participants, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol.

Age, Categorical
Age, Categorical(Participants)PlaceboLebrikizumab Q2WTotal
<=18 years173350
Between 18 and 65 years123239362
>=65 years102333
Age, Continuous
Age, Continuous(years)PlaceboLebrikizumab Q2WTotal
Mean35.6 ± 17.1536.5 ± 16.6436.2 ± 16.80
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLebrikizumab Q2WTotal
Female79147226
Male71148219
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboLebrikizumab Q2WTotal
American Indian or Alaska Native235
Asian4478122
Native Hawaiian or Other Pacific Islander123
Black or African American102636
White89181270
More than one race347
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(Participants)PlaceboLebrikizumab Q2WTotal
Canada164258
Singapore81119
United States64121185
Taiwan213960
Ukraine3811
Mexico369
Bulgaria71522
Germany285381
08

Study locations

89 sites
  • Investigate MD
    Scottsdale, Arizona 85255, United States
  • Northwest Arkansas Clinical Trials Center
    Rogers, Arkansas 72758, United States
  • Bakersfield Dermatology and Skin Cancer Medical Group
    Bakersfield, California 93309, United States
  • Center For Dermatology Clinical Research, Inc.
    Fremont, California 94538, United States
  • Woodward Centre
    Fresno, California 93720, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • LA Universal Research Center, INC
    Los Angeles, California 90057, United States
  • University Clinical Trials, Inc.
    San Diego, California 92123, United States
  • San Luis Dermatology & Laser Clinic
    San Luis Obispo, California 93405, United States
  • Clinical Physiology Associates, Clinical Study Center
    Fort Myers, Florida 33916-9452, United States
  • Direct Helpers Medical Center
    Hialeah, Florida 33012, United States
  • The Community Research of South Florida
    Hialeah, Florida 33016, United States
  • Solutions Through Advanced Research, Inc.
    Jacksonville, Florida 32256, United States
  • Georgia Pollens Clinical Research Centers, Inc
    Albany, Georgia 31707, United States
  • Marietta Dermatology Clinical Research
    Marietta, Georgia 30060, United States
  • Advanced Medical Research
    Sandy Springs, Georgia 30328, United States
  • Arlington Dermatology
    Rolling Meadows, Illinois 60008, United States
  • NorthShore University HealthSystem
    Skokie, Illinois 60077, United States
  • Kansas City Dermatology, PA
    Overland Park, Kansas 66215, United States
  • Meridian Clinical Research
    Baton Rouge, Louisiana 70808, United States
  • ActivMed Practices and Research
    Beverly, Massachusetts 01915, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Great Lakes Research Group, Inc.
    Bay City, Michigan 48706, United States
  • Clarkston Skin Research
    Clarkston, Michigan 48346, United States
  • Associated Skin Care Specialists
    Fridley, Minnesota 55432, United States
  • Central Dermatology PC
    Saint Louis, Missouri 63117, United States
  • Forest Hills Dermatology Group
    Kew Gardens, New York 11415, United States
  • OnSite Clinical Solutions
    Charlotte, North Carolina 28277, United States
  • Wilmington Dermatology Center
    Wilmington, North Carolina 28405, United States
  • Dermatology and Skin Surgery Center
    Exton, Pennsylvania 19341, United States
  • DermDOX
    Hazleton, Pennsylvania 18201, United States
  • Peak Research LLC
    Upper Saint Clair, Pennsylvania 15241, United States
  • Dermatology & Laser Center of Charleston
    Charleston, South Carolina 29407, United States
  • Palmetto Clinical Trial Services
    Greenville, South Carolina 29601, United States
  • Arlington Research Center, Inc
    Arlington, Texas 76011, United States
  • Innovate Research, LLC
    Fort Worth, Texas 76244, United States
  • Austin Institute for Clinical Research
    Pflugerville, Texas 78660, United States
  • University of Utah MidValley Dematology
    Murray, Utah 84107, United States
  • Virginia Clinical Research, Inc.
    Norfolk, Virginia 23502, United States
  • Dermatology Associates
    Seattle, Washington 98101, United States
  • DCC Sveti Georgi
    Plovdiv, 4000, Bulgaria
  • Diagnostic and Consultation Center 14
    Sofia, 1408, Bulgaria
  • Alexandrovska University Hospital
    Sofia, 1432, Bulgaria
  • Euro Derma clinic
    Sofia, 1606, Bulgaria
  • Military Medical Academy
    Sofia, 1606, Bulgaria
  • Medical centre Alitera-Med EOOD
    Sofia, 1618, Bulgaria
  • Dr. Chih-ho Hong Medical Inc.
    Surrey, British Columbia V3R 6A7, Canada
  • Simcoderm Medical & Surgical Dermatology Centre
    Barrie, Ontario L4M 7G1, Canada
  • Lynderm Research Inc.
    Markham, Ontario L3P1X2, Canada
  • North York Research Inc.
    North York, Ontario M2M4J5, Canada
  • Ottawa Allergy Research Corp
    Ottawa, Ontario K1G 6C6, Canada
  • K. Papp Clinical Research
    Waterloo, Ontario N2J 1C4, Canada
  • Derma-Study-Center Friedrichshafen GmbH
    Friedrichshafen, Baden-Württemberg 88045, Germany
  • Studienzentrum Dr.Beate Schwarz
    Langenau, Baden-Württemberg 89129, Germany
  • Hautarztpraxis am Löwenmarkt
    Stuttgart, Baden-Württemberg 70499, Germany
  • licca Fachklinik
    Augsburg, Bayern 86179, Germany
  • Rosenpark Research Geschäftsbereich der Rosenparkklinik GmbH
    Darmstadt, Hessen 64283, Germany
  • Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
    Frankfurt am Main, Hessen 60590, Germany
  • Elbe Klinikum Buxtehude
    Buxtehude, Niedersachsen 21614, Germany
  • Klinische Forschung Osnabrück
    Osnabrück, Niedersachsen 49074, Germany
  • Fachklinik Bad Bentheim
    Bad Bentheim, Nordrhein-Westfalen 48455, Germany
  • Hautzentrum im Jahrhunderthaus
    Bochum, Nordrhein-Westfalen 44793, Germany
  • Universitätsklinikum Münster
    Münster, Nordrhein-Westfalen 48149, Germany
  • Universität Leipzig - Universitätsklinikum
    Leipzig, Sachsen 04103, Germany
  • SIBAmed Studienzentrum GmbH & Co. KG
    Leipzig, Saxony 04103, Germany
  • Universitätsklinikum Schleswig-Holstein
    Lübeck, Schleswig-Holstein 23538, Germany
  • Praxis Dr. Michael Dietlen
    Augsburg, 86150, Germany
  • Charité Universitätsmedizin Berlin Campus Buch
    Berlin, 10117, Germany
  • ISA GmbH
    Berlin, 10789, Germany
  • Praxis für Ganzheitliche Dermatologie im Ärztehaus
    Berlin, 13055, Germany
  • Universitätsklinikum Hamburg
    Hamburg, 20246, Germany
  • TFS Trial Form Support GmbH
    Hamburg, 20537, Germany
  • Clinica De Enfermedades Cronicas y Procedimientos Especiales
    Morelia, Michoacan Morelia CP 58249, Mexico
  • Derma Norte del Bajío, S.C.
    Aguascalientes, 20130, Mexico
  • National University Hospital
    Singapore, 119074, Singapore
  • Singapore General Hospital
    Singapore, 169078, Singapore
  • Kk Women'S and Childrens Hospital
    Singapore, 229899, Singapore
  • National Skin Centre NSC
    Singapore, 308205, Singapore
  • Kaohsiung Chang Gung Memorial Hospital
    Niaosong Dist, Kaohsiung City 833, Taiwan
  • Kaohsiung Medical University Chung-Ho Institutional Review B
    Kaohsiung, 807, Taiwan
  • Taipei Medical University- Shuang Ho Hospital
    New Taipei City, 235, Taiwan
  • China Medical University Hospital
    Taichung City, 40447, Taiwan
  • Chung Shan Medical University Hospital
    Taichung, 402, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
  • Chang Gung Memorial Hospital - Linkou
    Taoyuan City, 33305, Taiwan
  • Municipal Healthcare Institution Kharkiv City Dermatoverenologic Dispensary N2
    Kharkiv, 61038, Ukraine
  • Rivne Regional Dermatology and Venereology Dispensary
    Rivne, 39028, Ukraine
  • Treatment-diagnostic center PE "Asclepius"
    Uzhhorod, 88002, Ukraine
  • Community Institution Zaporizhzhya Regional Dermatovenereology Clinical Hospital of Zaporizhzhya Regional Council
    Zaporizhzhya, 69000, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Jul 2021, 20 months.

Results were first posted in Sep 2022, 1 year 2 months after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 20 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2019
First posted
Nov 26, 2019
StartActual
Oct 29, 2019
Primary completionActual
Jul 12, 2021
CompletionActual
Apr 28, 2022
Results first posted
Sep 16, 2022
Last update
May 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04178967
Collaborators
Dermira, Inc.
Responsible party
Sponsor
First posted
Nov 26, 2019
Start date
Oct 29, 2019
Primary completion
Jul 12, 2021
Completion
Apr 28, 2022
Results posted
Sep 16, 2022
Last update
May 24, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion